People who inject drugs (PWID) are a key population for the elimination of hepatitis C in Europe, and increasing their access to HCV testing and care is a goal in European and national hepatitis C policies. Despite this, HCV testing remains low among people who inject drugs and effective approaches to promote testing as the first element of a cascade of care are particularly needed.
Eliminating hepatitis C in prisons will be a crucial setting if World Health Organization (WHO) elimination targets are to be achieved. For World Hepatitis Day, we’ll hear from experts about the evidence that treatment as prevention in prisons works, and how it can be rolled out in Australia to have the most effective impact.
Background: The impact of Hepatitis C virus (HCV) RNA levels on the evolution of chronic HCV infection-related liver damage is controversial. Heavy alcohol use is believed to have a deleterious impact on the course of HCV disease, but current knowledge about the possible effect of alcohol use on HCV RNA levels in HIV/HCV coinfected patients is limited.
This knowledge questionnaire has been developed by the EMCDDA as part of its initiative to increase access to hepatitis C care through drug services. The main aims of the knowledge questionnaire are:
The opioid epidemic has resulted in significant increases in Hepatitis C Virus (HCV) among people who inject drugs, accounting for 23% of new infections. HCV is completely curable and testing and treatment are the path to cure. Opioid Treatment Providers (OTPs) play a critical role in comprehensive approaches to addressing HCV and this guide is one tool to help.
Australia is a world leader in its efforts to eliminate hepatitis C and to improve the health of people who use drugs. But COVID-19, on a backdrop of economic uncertainty, anxiety and unemployment has the potential to disrupt our support, prevention and cure efforts – especially given the populations most impacted by hepatitis C and drug dependence are some of our most vulnerable Australians.
The 9th International Conference on Hepatitis Care in Substance Users will be held in Glasgow, Scotland, 8 – 10 October 2020.
The INHSU annual conference is a unique opportunity to connect with the global community working to improve health outcomes for people who use drugs including the prevention, treatment and care of hepatitis C.
This FREE one day conference, organised by Hepatitis Scotland, is aimed at staff who work in, or have strategic responsibility for, primary and secondary care addiction services.
The day will explore the background to developing successful hepatitis C case-finding initiatives, demonstrating real world successes and issues for practitioners to consider.